Company intelligence / Profile preview

Radionetics Oncology

San Diego, California, United Statesradionetics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Radionetics Oncology has initiated a Phase I study for its lead candidate, a gallium-based radioligand conjugate targeting MC2R in adrenocortical carcinoma. The company plans additional clinical programs in breast and lung cancers. Its approach leverages novel GPCR targets with small molecule precision for selective tumor targeting using radioactive payloads.

Therapeutic areas: Oncology
Modalities: Small molecule radioligandsRadiopharmaceuticalsNonpeptide-targeted radiotherapeutics
Industry: Biotech

Drug pipeline

5 assets

Radion-pdt

4 more assets in the full pipeline.

Partnerships

Eli Lilly & Company – $140M upfront payment for access to pipeline/platform plus exclusive future acquisition right ($1B option)Crinetics Pharmaceuticals – technology licensing/research collaboration agreement at formation

Beyond the preview

Go deeper on Radionetics Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Radionetics Oncology.